Adlai Nortye Ltd. (ANL)Healthcare | Biotechnology | Grand Cayman, Cayman Islands | NasdaqGM
16.01 USD
+2.32
(16.947%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 15.60 -0.41 (-0.410%) ⇩ (April 17, 2026, 7:54 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:14 p.m. EDT
ANL appears to be a highly volatile stock with a negative beta, indicating it moves inversely to the market. The recent price history shows significant fluctuations, with a recent dip to $6.46 followed by a rebound to $12.03, but the current price is at $11.16. The forward P/E is negative, suggesting potential earnings issues, and the company has a negative return on equity and assets, indicating poor financial performance. The market cap has increased, but this may be due to retail investor activity rather than fundamental improvements. The lack of dividends and the negative earnings per share suggest it is not a good candidate for dividend investors. The short-term momentum is mixed, with a recent uptick but overall uncertainty. Long-term investors should be cautious due to the weak fundamentals and negative financial metrics. Overall, this stock is not recommended for either short-term or long-term investment at this time. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.724519 |
| AutoARIMA | 0.903845 |
| AutoETS | 0.903856 |
| MSTL | 0.944271 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 0.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.056 |
| Excess Kurtosis | 0.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.156 |
| Market Cap | 849,765,888 |
| Forward P/E | -45.10 |
| Beta | -0.71 |
| Website | https://www.adlainortye.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 7.005848 |
| Address1 | Ugland House |
| Address2 | PO Box 309 |
| All Time High | 19.3 |
| All Time Low | 0.879 |
| Ask | 19.22 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 782,980 |
| Average Daily Volume3 Month | 696,414 |
| Average Volume | 696,414 |
| Average Volume10Days | 782,980 |
| Beta | -0.707 |
| Bid | 12.14 |
| Bid Size | 2 |
| Book Value | -0.208 |
| City | Grand Cayman |
| Country | Cayman Islands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.01 |
| Current Ratio | 0.646 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 16.974 |
| Day Low | 13.2 |
| Display Name | Adlai Nortye |
| Earnings Timestamp End | 1,755,864,000 |
| Earnings Timestamp Start | 1,754,650,740 |
| Ebitda | -34,935,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -55.492 |
| Enterprise To Revenue | 387.725 |
| Enterprise Value | 1,938,625,792 |
| Eps Current Year | -0.22667 |
| Eps Forward | -0.355 |
| Eps Trailing Twelve Months | -1.11 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.2184 |
| Fifty Day Average Change | 6.7916 |
| Fifty Day Average Change Percent | 0.7367439 |
| Fifty Two Week Change Percent | 700.5848 |
| Fifty Two Week High | 16.974 |
| Fifty Two Week High Change | -0.9640007 |
| Fifty Two Week High Change Percent | -0.05679278 |
| Fifty Two Week Low | 0.879 |
| Fifty Two Week Low Change | 15.1310005 |
| Fifty Two Week Low Change Percent | 17.21388 |
| Fifty Two Week Range | 0.879 - 16.974 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,695,994,200,000 |
| Float Shares | 61,872,413 |
| Forward Eps | -0.355 |
| Forward P E | -45.098595 |
| Free Cashflow | -37,687,248 |
| Full Exchange Name | NasdaqGM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 5,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05659 |
| Held Percent Institutions | 0.06894 |
| Implied Shares Outstanding | 53,077,191 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-09-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and develops pharmaceutical products in the United States and internationally. Its lead product is AN8025, a tri-functional fusion protein of aPD-L1 x CD86 variant x LAG3 variant, a T-cell and antigen-presenting cell modulator, which is in phase 1a clinical trials for the treatment of tumor. The company also developing AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers include pancreatic, lung, and colorectal adenocarcinomas; and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which is in phase 1b treatment for tumor to activate cancer immunity. It is also developing AN0025, a small molecule EP4 antagonist, which is in phase 1b clinical trials for the treatment of locally advanced esophageal cancer (+chemoradiation therapy), and radiotherapy which is in phase 2 clinical trials for the treatment of rectal cancer (+chemoradiation therapy). Adlai Nortye Ltd. was founded in 2004 and is based in Grand Cayman, the Cayman Islands. |
| Long Name | Adlai Nortye Ltd. |
| Market | us_market |
| Market Cap | 849,765,888 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1830112145 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -35,528,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 849,235,050 |
| Number Of Analyst Opinions | 3 |
| Open | 14.0 |
| Operating Cashflow | -33,452,000 |
| Operating Margins | -3.3048 |
| Payout Ratio | 0.0 |
| Phone | 848 230 7430 |
| Post Market Change | -0.40999985 |
| Post Market Change Percent | -2.5608985 |
| Post Market Price | 15.6 |
| Post Market Time | 1,776,470,055 |
| Previous Close | 13.69 |
| Price Eps Current Year | -70.63132 |
| Price Hint | 2 |
| Price To Book | -76.97115 |
| Price To Sales Trailing12 Months | 169.95317 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.216 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 2.32 |
| Regular Market Change Percent | 16.9467 |
| Regular Market Day High | 16.974 |
| Regular Market Day Low | 13.2 |
| Regular Market Day Range | 13.2 - 16.974 |
| Regular Market Open | 14.0 |
| Regular Market Previous Close | 13.69 |
| Regular Market Price | 16.01 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,385,960 |
| Return On Assets | -0.42215002 |
| Return On Equity | -4.14007 |
| Revenue Growth | 1.781 |
| Revenue Per Share | 0.156 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 47,413,857 |
| Shares Percent Shares Out | 0.0214 |
| Shares Short | 1,257,504 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 837,841 |
| Short Name | Adlai Nortye Ltd. |
| Short Percent Of Float | 0.0239 |
| Short Ratio | 6.89 |
| Source Interval | 15 |
| Symbol | ANL |
| Target High Price | 46.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 28.33333 |
| Target Median Price | 23.0 |
| Total Cash | 8,963,000 |
| Total Cash Per Share | 0.075 |
| Total Debt | 26,376,000 |
| Total Revenue | 5,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.66802 |
| Two Hundred Day Average Change | 12.34198 |
| Two Hundred Day Average Change Percent | 3.3647525 |
| Type Disp | Equity |
| Volume | 1,385,960 |
| Website | https://www.adlainortye.com |
| Zip | KY1-1104 |